New Drug Approvals
| 1 | Marzulene S Combination Granules | Gastritis, Gastric ulcer, duodenal ulcer therapeutic agent （1968：Japan, 1990：China, 2000：India） “Granule mass-production technology” | |||
| Marzulene Combination Tablets 1.0ES | （Dosage form addition, 2003：Japan） | ||||
| Marzulene Combination Tablets 0.5ES | （Dosage form addition, 2008：Japan） | ||||
| Marzulene Combination Tablets 0.375ES | （Dosage form addition, 2009：Japan） | ||||
| 2 | AZULOXAⓇ Granules 2.5% | Gastric ulcer therapeutic agent （2001：Japan, 2004：Korea） | |||
| AZULOXAⓇ Tablets 15mg | （Dosage form addition, 2011：Japan） | ||||
| 3 | SuglatⓇ Tablets 25mg/50mg （Ipragliflozin (ASP1941) ） | Diabetes therapeutic agent/Selective SGLT2 Inhibitor （Type 2 Diabetes, 2014：Japan, 2015：Korea, 2019：Russia, Joint development with Astellas Pharma Inc.） （Type 1 Diabetes, 2018：Japan, Joint development with Astellas Pharma Inc.） | |||
| 4 | SUJANUⓇ Combination Tablets （Ipragliflozin/Sitagliptin (MK-0431J) ） | Type 2 Diabetes therapeutic agent/Selective DPP-4 inhibitor/Selective SGLT2 Inhibitor （2018：Japan, Joint development with Astellas Pharma Inc and MSD.） | |||
| 5 | XOSPATAⓇ Tablets 40mg （giliteritinib (ASP2215) ） | Antineoplastic drug/FLT3 Mutation |
R&D Pipeline（2025.12）
| 1 | ASP1570 | ①Development stage：Global/Phase Ⅰ ②Target：Cancer ③Development：Astellas | ||
| 2 | XOSPATA®(gilteritinib, ASP2215) | ①Development stage：Global/Phase Ⅲ ②Target：Acute myeloid leukemia ③Development：Astellas | ||
| ①Development stage：Global/Phase Ⅰ ②Target：ALK-positive non-small cell lung cancer (NSCLC) ③Development：Astellas | ||||
| 3 | KT6-971 | ①Development stage：Japan/Phase Ⅱ, Europe/Phase I ②Target：Dyslipidemia ③Development：Kotobuki | ||
| 4 | KT7-533: α-C-Galactosyl Ceramide
| （Phase I in preparation：licensing-out） |
Medicinal Chemistry
Azulene Chemistry; Carbohydrate Chemistry; Transporter Inhibitor; Kinase Inhibitor;
Enzyme Inhibitor; Receptor Antagonist; Protein-Protein Interaction Inhibitor; Immunity
Pharmaceutical Engineering
Combination Granule; Combination Tablet; Easy-to-Swallow Tablet; Easy-to-Split Tablet (by fingers); Improved-Visibility Tablet;
Enteric-Coated Tablet; Patient-Friendly PTP Packaging (with improved visibility); Bitterness Reduction Technology; Miniaturized Tablet;
Capsule to Tablet Conversion; Kawara OD Tablet®; Film-Coated Orally Disintegrating Tablet (Coat OD Tablet®);
Gel-Coated Tablet (Gel-Coat Tablet®)
＊Kotobuki Pharma retains all IP rights of “Kawara OD Tablet®” , “Coat OD Tablet®” and “Gel-Coat Tablet®”.
